Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13018707 | 0.93 | CSF1R (0.84) | CSF1RNTRK1 | |
| SCHEMBL765347 | 0.93 | CSF1R (0.82) | CSF1RNTRK1 | |
| SCHEMBL13018437 | 0.91 | CSF1R (1.00) | CSF1RNTRK1 | |
| SCHEMBL13018716 | 0.91 | CSF1R (1.00) | CSF1RNTRK1 | |
| SCHEMBL13018799 | 0.91 | CSF1R (1.00) | CSF1RNTRK1 | |
| SCHEMBL13018577 | 0.91 | CSF1R (0.82) | CSF1RNTRK1 | |
| SCHEMBL13018606 | 0.89 | CSF1R (0.79) | CSF1RNTRK1 | |
| SCHEMBL13018434 | 0.89 | CSF1R (0.88) | CSF1RNTRK1 | |
| SCHEMBL13018789 | 0.89 | CSF1R (0.88) | CSF1RNTRK1 | |
| SCHEMBL741900 | 0.88 | CSF1R (0.75) | CSF1RNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765739-B2 | Azetidine compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765739-B2 | Azetidine compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2431365-A1 | AZETIDINE COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| WO-2010131738-A1 | AZETIDINE COMPOUND AND MEDICINAL USE THEREOF | 日本たばこ産業株式会社 (JP) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331301-A1 | AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF | CYP2C19, CYP2C9, QDPR | CSF1R 2860/4885NTRK1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.